Morningstar

Vertex Pharmaceuticals Inc VRTX

Morningstar Rating
Unlock
Stock XNAS Rating as of
$446.83 +5.09 (1.15%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Price vs Fair Value

View History
VRTX is trading at a 549% premium.
Price
$446.83
Fair Value
$365.00
Uncertainty
High
1-Star Price
$533.10
5-Star Price
$683.00
Economic Moat
Ggbyrny
Capital Allocation
Ytfcybzh

Bulls Say, Bears Say

Bulls

The firm's CF therapies are poised to dominate the lucrative market for the foreseeable future, based on the disease-modifying potential of the drugs, chronic use by patients, and limited competition.

Bears

Vertex is highly dependent on the success of its cystic fibrosis franchise, and it could fail to diversify if its other pipeline candidates are not successful.

Show More

News

View All

Trading Information

Previous Close Price
$441.74
Day Range
$443.86–453.16
52-Week Range
$362.50–507.92
Bid/Ask
$444.00 / $446.35
Shares Outstanding
253.81M
Market Cap
$113.41B
Volume/Avg
2M / 1M

Key Statistics

Price/Earnings (Normalized)
23.74
Price/Sales
9.41
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
1.99%

Company Profile

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Value
Total Number of Employees
6,400
Website
https://www.vrtx.com

Competitors

Valuation

View More
Metric
VRTX
ALNY
GMAB
Price/Earnings (Normalized)
 23.7446.6914.49
Price/Book Value
 5.8737.612.62
Price/Sales
 9.419.673.95
Price/Cash Flow
 23.3333.4817.81
Price/Earnings
VRTX
ALNY
GMAB

Financial Strength

Metric
VRTX
ALNY
GMAB
Quick Ratio
 2.382.882.17
Current Ratio
 3.023.132.18
Interest Coverage
 —2.686.45
Quick Ratio
VRTX
ALNY
GMAB

Profitability

Metric
VRTX
ALNY
GMAB
Return on Assets (Normalized)
 19.53%18.61%12.45%
Return on Equity (Normalized)
 27.18%179.16%20.24%
Return on Invested Capital (Normalized)
 22.65%59.07%14.93%
Return on Assets
VRTX
ALNY
GMAB

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Regeneron Pharmaceuticals Inc
REGN
RlyxvwnnWjtfsq$67B
 argenx SE ADR
ARGX
WlmwgjqgBvl$55B
 Alnylam Pharmaceuticals Inc
ALNY
DlcmtlnDgdcfm$40B
 Royalty Pharma PLC Class A
RPRX
KwfssgbmzxNtkrmbx$25B
 BioNTech SE ADR
BNTX
LbqltgxbYypb$22B
 Incyte Corp
INCY
VgttncytNnsf$20B
 Moderna Inc
MRNA
VspqcpyZnt$19B
 Jazz Pharmaceuticals PLC
JAZZ
FgdmpcdCfc$15B
 BridgeBio Pharma Inc
BBIO
NsqmwksyCxrt$13B

Sponsor Center